PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxcyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$63.68+0.06 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $9.20B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
+$21.29 (+50.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $9.20B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.34
- Dividend yield
- 0.00%
- Free cash flow yield
- -9.72%
Fundamentals
- Net income
- -$1.06B
- EPS, diluted
- -$7.64
- Free cash flow
- -$894.14M
- Book value per share
- $19.09
- Diluted shares
- 144M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
-$1.17B
Net income
-$1.06B
EPS, diluted
-$7.64
Free cash flow
-$894.14M
Reported periodTrailing twelve months